| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 29.43 | 13.0% | 82.1% |
| Total Income | 29.43 | 13.0% | 82.1% |
| Expenditure | 42.96 | 11.9% | 78.4% |
| PBT | -13.29 | 36.3% | 89.3% |
| Net Profit | -13.20 | 38.1% | 88.0% |
| OPM | -45.98% | 1.44pp | 3.01pp |
| NPM | -44.85% | 37.06pp | 1.40pp |
| EPS | -0.22 | 87.4% | 64.5% |
Alamar Biosciences Reports Q2 2026 Financial Results and Provides 2026 Revenue Guidance
11 Aug 2026 · 11 Aug, 1:45 am
Summary
Alamar Biosciences reported strong second quarter 2026 financial results, with total revenue reaching $29.4 million, an 82% increase year-over-year. This growth was driven by significant increases in both consumable revenue (up 147%) and instrument revenue (up 35%). The company also saw an improvement in gross margin to 60% from 53% in the prior year period. Management provided full-year 2026 revenue guidance between $116 million and $120 million, projecting 59% growth at the midpoint.
Key Highlights
- 1
Alamar Biosciences generated $29.4 million of total revenue for the second quarter of 2026, an increase of 82% as compared to the corresponding period of 2025.
- 2
Consumable revenue grew 147% to $15.5 million, from $6.3 million for the corresponding prior-year period, driven primarily by strong demand for multiplex panels.
- 3
Instrument revenue grew 35% to $7.8 million, from $5.8 million for the corresponding prior-year period, driven primarily by continued growth in new instrument placements.
- 4
Gross margin was 60% for the second quarter of 2026, as compared to 53% for the corresponding prior-year period, driven by manufacturing efficiencies and a favorable shift in mix toward high-margin consumables.
- 5
The company launched the first commercial multiplexed blood-based immunoassay for eMTBR-tau, available in their NULISAseq™ Neuro 220 Panel and through their Technology Access Program.
- 6
Alamar Biosciences is providing full-year 2026 revenue guidance of $116 million to $120 million, representing growth of 59% at the midpoint of the range as compared to 2025.
Management Comments
Yuling Luo
We delivered a strong second quarter with consumable revenue growing nearly 150% year-over-year. With the recent launches of eMTBR-tau and the Immune 340 Panel strengthening our content menu and extending into new disease areas, we believe we are well-positioned to sustain momentum into the coming quarters.
Informational and educational content only. Not investment advice.